Back to Search
Start Over
SWI/SNF complex subunit BAF60a represses hepatic ureagenesis through a crosstalk between YB-1 and PGC-1α
- Source :
- Molecular Metabolism, Molecular Metabolism, Vol 32, Iss, Pp 85-96 (2020)
- Publication Year :
- 2019
- Publisher :
- Elsevier, 2019.
-
Abstract
- Objective Ureagenesis predominantly occurs in the liver and functions to remove ammonia, and the dysregulation of ureagenesis leads to the development of hyperammonemia. Recent studies have shown that ureagenesis is under the control of nutrient signals, but the mechanism remains elusive. Therefore, intensive investigation of the molecular mechanism underlying ureagenesis will shed some light on the pathology of metabolic diseases related to ammonia imbalance. Methods Mice were fasted for 24 h or fed a high-fat diet (HFD) for 16 weeks. For human evaluation, we obtained a public data set including 41 obese patients with and without hepatic steatosis. We analyzed the expression levels of hepatic BAF60a under different nutrient status. The impact of BAF60a on ureagenesis and hyperammonemia was assessed by using gain- and loss-of-function strategies. The molecular chaperons mediating the effects of BAF60a on ureagenesis were validated by molecular biological strategies. Results BAF60a was induced in the liver of both fasted and HFD-fed mice and was positively correlated with body mass index in obese patients. Liver-specific overexpression of BAF60a inhibited hepatic ureagenesis, leading to the increase of serum ammonia levels. Mechanistically, BAF60a repressed the transcription of Cps1, a rate-limiting enzyme, through interaction with Y-box protein 1 (YB-1) and by switching the chromatin structure of Cps1 promoter into an inhibitory state. More importantly, in response to different nutrient status, PGC-1α (as a transcriptional coactivator) and YB-1 competitively bound to BAF60a, thus selectively regulating hepatic fatty acid β-oxidation and ureagenesis. Conclusion The BAF60a-YB-1 axis represses hepatic ureagenesis, thereby contributing to hyperammonemia under overnutrient status. Therefore, hepatic BAF60a may be a novel therapeutic target for the treatment of overnutrient-induced urea cycle disorders and their associated diseases.<br />Graphical abstract Image 1<br />Highlights • HFD-feeding increases hepatic BAF60a expression, while inhibits ureagenesis genes. • BAF60a represses Cps1 transcription and ureagenesis, causing ammonia accumulation. • YB-1 binds to BAF60a and mediates the inhibitory effects of BAF60a on ureagenesis. • BAF60a mediates crosstalk between hepatic ureagenesis and fatty acid oxidation.
- Subjects :
- 0301 basic medicine
Male
medicine.medical_specialty
lcsh:Internal medicine
BAF60a
Chromosomal Proteins, Non-Histone
Protein subunit
030209 endocrinology & metabolism
YB-1
03 medical and health sciences
Mice
0302 clinical medicine
Transcription (biology)
Internal medicine
Nutrient signals
medicine
Animals
Urea
Hyperammonemia
Urea cycle
lcsh:RC31-1245
Molecular Biology
chemistry.chemical_classification
Fatty acid
Cell Biology
medicine.disease
Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha
Chromatin
Mice, Inbred C57BL
030104 developmental biology
Endocrinology
Enzyme
chemistry
Liver
Original Article
Steatosis
Transcription Factors
Subjects
Details
- Language :
- English
- ISSN :
- 22128778
- Volume :
- 32
- Database :
- OpenAIRE
- Journal :
- Molecular Metabolism
- Accession number :
- edsair.doi.dedup.....9c26a27a8b8ad160c1424cc847c3d41e